Mixed results with baricitinib in biological-resistant adult-onset Still’s disease and undifferentiated systemic autoinflammatory disease by Kacar, M et al.
CLINICAL CASE
Mixed results with baricitinib in
biological-resistant adult-onset Still’s
disease and undifferentiated systemic
autoinflammatory disease
Mark Kacar,1 John Fitton,2 Andrew K Gough,3 Maya H Buch ,1
Dennis G McGonagle,2 Sinisa Savic 2,4
ABSTRACT
This clinical case series describes our experience with the
use of Janus kinase 1/2 inhibitor baricitinib in two patients
suffering from refractory adult-onset Still’s disease (AOSD)
as well as in one case suffering from AOSD-like
autoinflammatory disease in the context of myelodysplastic
syndrome. All patients suffered from disease non-
responsive to conventional Disease-modifying
antirheumatic drugs (DMARDs) as well as biological
therapies including interleukin (IL)-1 and IL-6 blockade,
relying instead on high daily doses of prednisolone. We also
report the first case of Pneumocystis jirovecii infection
following baricitinib use.
INTRODUCTION
Adult-onset Still’s disease (AOSD) is a rare sys-
temic autoinflammatory disorder characterised
by a combination of fever, generalised evanes-
cent salmon-pink rash, pharyngodynia, arthri-
tis/synovitis, lymphadenopathy, serositis and
splenomegaly. None of these clinical features
are disease-specific, and a wide spectrum of
conditions including autoimmune, infectious
and malignant diseases need to be considered
as part of differential diagnosis. Several classifi-
cation criteria have been developed for
research purposes that can aid the diagnosis of
AOSD. The most commonly used are
Yamaguchi’s1 and Fautrel’s2 criteria with the
latter one not requiring exclusion of other con-
ditions for diagnosis of AOSD to be made. The
diagnosis can be particularly difficult in patients
with pre-existing conditions such as myelodys-
plastic syndrome (MDS) or in patients who do
not fulfil all classification criteria, but have
a condition closely resembling AOSD and who
are ultimately treated and respond to therapies
used for AOSD. A frequently used diagnostic
label in such cases is that of undifferentiated
systemic autoinflammatory syndrome
(uSAID).3
Treatment of AOSD has been revolutio-
nised by the introduction of biologicals
DMARD particulary those targeting interleu-
kin (IL)-1 and IL-6.4–7 The Janus kinase (JAK)
inhibitors—tofacitinib, baricitinib and others
—are highly effective in refractory inflamma-
tory arthritis, including patients who have
failed biological therapy.8 9 Here, we describe
our experience using the JAK-1/JAK-2 inhibi-
tor baricitinib in two patients with biological-
resistant AOSD meeting Yamaguchi’s diag-
nostic criteria, as well as in one patient suffer-
ing from anAOSD-like disorder in the context
of low-grade MDS. Results of relevant investi-
gations are shown in table 1, a summary of
medications used (and their doses) are
shown in table 2, and clinical characteristics,
laboratory results and concomitant medica-
tion prebaricitinib and postbaricitinib imple-
mentation are shown in table 3.
CASE REPORT
A 43-year-old Sudanese woman (P1) was first
treated at in Sudan (at 41 years) for fever and
flitting arthralgia. She relapsed in the UK
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What is already known about this subject?
► Cytokine inhibition (IL-1 and IL-6) using bilogicals is
now established treatment approach in AOSD.
What does this study add?
► JAKi should be tried in patients who fail bilologics 3.
How might this impact on clinical practice?
► Additional studies are needed to determine optimal
place for use of JAKi in treatment AOSD.
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despite maintenance therapy with prednisolone and hydro-
xychloroquine, presenting with fever, arthritis/synovitis and
evanescent rash in the context of neutrophilia and elevated
inflammatory markers. She remained steroid-dependent
(multiple unsuccessful tapers below 15 mg prednisolone
daily) despite combination therapy with anakinra and
Table 1 Demographics, clinical characteristics and results
Patient 1 (P1) Pateint 2 (P2) Pateint 3 (P3)
Gender F M F
Age at presentation (years) 41 29 58
Clinical characteristics at presentation
Fevers >39°Ct* + + +
Joint involvement† + + +
Rash‡ + + −
Sore throat + − +
Lymphadenopathy − − −
Splenomegaly + − −
Serositis + − −
Laboratory results
ANA/RF − − −
WBC >10.000/mL + +^ −‘
Elevated LFTs (>1.5X ULN) + (ALT, AP, LDH) + (ALT) + (AP)
Maximum CRP (<10 mg/L) 231mg/L (on 35 mg
Pred/day)
94 mg/L (on 40 mg
Pred/day)
239 mg/L (on 20 mg
Pred/day)
Maximum ESR (1–15 m/hour) 125 mm/hour 16 mm/hour NA
Maximum ferritin (10–332 ng/mL) 38 940 ng/mL 679 ng/mL 2695 ng/mL’’









malignancy or vasculitis; USS
abdomen—no abnormalities
detected
*Lasting 1 week or longer.
†Arthritis/synovitis/arthralgia.
‡Evanescent, salmon-pink maculopapular rash.
‘P3 has been pancytopenic since presentation due to underlying myelodysplasia; however, flares were associated with tripling of neutrophil
counts. ‘’The elevation of ferritin does not correspond to disease flares but likely reflects increased transfusion dependence. ^WBC over 13.000
but 77% PBMC.
ALT, alanine aminotransferase; ANA, antinuclear antibody assay; AP, alkaline phosphatase; CRP, C reactive protein; ESR, erythrocyte
sedimentation rate; F, female; LDH, lactate dehydrogenase; LFT, liver function test; NA, not available; M, male; PET, positron emission
tomography; Pred, prednisolone; RF, rheumatoid factor; ULN, upper limit of normal; USS, ultrasound scan; WBC, white blood cell count.
Table 2 Treatments used before baricitinib implementation and their efficacy
P1 P2 P3
Prednisolone PR 30–40 mg OD PR 40 mg OD PR 20 mg OD
Methotrexate NR* 7.5 mg 1 weekly NR 25 mg 1 weekly / /
Ciclosporin PR 100 mg BD NR 150 mg BD / /
Anakinra PR 300 mg BD NR 100 mg BD NR 100 mg OD
Tocilizumab NR 8 mg/kg 2 weekly NR 8 mg/kg 2 weekly CR—vasculitis 162 mg 2 weekly





*In addition to lack of response, P1 experienced a severe generalised toxic drug eruption with MTX.
CR—complete response defined as resolution of all symptoms/absence of flares with normalisation of laboratory parameters.
PR—partial response defined as >50% reduction in frequency/severity of symptoms.
NR—no response.
OD—one time per day.
BD—two times per day.
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ciclosporin or methotrexate. Anakinra was briefly replaced
with two-weekly intravenous tocilizumab infusions but was
restarted due to primary non-response. The disease evolved
into a predominantly oligoarthritic phenotype with signifi-
cant synovial hypertrophy of both 2nd metacarpophalan-
geal (MCP) joints, multiple proximal interphalangeal joint
(PIP) joints and both knee supra-patellar pouches. In addi-
tion, there was evidence of bilateral tibialis posterior and
extensor carpi ulnaris tenosynovitis with evidence of multi-
ple early bone erosions on ultrasound. Baricitinib was
started at this point and the patient has remained in clinical
and biochemical remission while on baricitinib monother-
apy over the ensuing 15 months.
A 32-year-old Caucasian male (P2) presented at 29 years
with a flitting inflammatory polyarthritis (affecting hands,
wrists, elbows, shoulders and knees) associated with a non-
pruritic, evanescent rash, fevers, rigours and sweating. The
condition was responsive to high-dose prednisolone.
A diagnosis of AOSD was made and steroid-sparing immu-
nomodulatory therapy was initiated with ciclosporin, with
methotrexate added subsequently. Anakinra was added as
prednisolone requirement remained at least 15 mg/day,
with marked initial improvement but subsequent relapses
despite doubling and then tripling the dose. Two-weekly
intravenous tocilizumab was commenced in combination
with methotrexate, resulting in complete biochemical and
partial clinical response. After 6 months, he developed
a persistent urticaria-like rash, which improved only transi-
ently with the anti-IgE therapeutic, omalizumab. The
patient developed severe synovitis and baricitinib was
added without improvement. After 9 months, both drugs
were discontinued. Since then, the patient has received one
cycle of rituximab (to no effect) and more recently inflix-
imab with modest improvement in symptoms.
A 63-year-old Caucasian woman (P3) was diagnosed
with AOSD-like condition (uSAID) after presenting at
58 years with pharyngitis, fever and arthralgias. The
patient had pre-existing myelodysplasia diagnosed
2 years previously. Haematologist input deemed that her
symptoms were not due to MDS, which was low grade and
according to the MDS International Prognostic Scoring
System had low scores and therefore minimal possibility
of malignant transformation. Her MDS has remained
clinically unchanged to this date. The initial flare was
treated with high-dose corticosteroids. DMARDs were
omitted due to the patient’s MDS. She was established










CRP (<10 mg/L) 231 mg/L 94 mg/L 48 mg/L
ESR (1–15 m/hour) 125 mm/hour 16 mm/hour NA
Ferritin (10–332 ng/mL) 38 940 ng/mL 679 ng/mL 1812 ng/mL’’
PrebaricitinibX therapy
Prednisolone 10 mg OD 40 mg OD 15 mg OD
Methotrexate / 25 mg 1 weekly /
Ciclosporin 100 mg OD 150 mg BD /
Anakinra 300 mg OD 100 mg BD /
Tocilizumab 8 mg/kg 2 weekly 8 mg/kg 2 weekly /
Sarilumab / / /








CRP (<10 mg/L) <5 mg/L 56 mg/L 2 mg/L
ESR (1–15 m/hour) 17 mm/hour 9 mm/hour NA
Ferritin (10–332 ng/mL) 18 ng/mL 304 ng/mL 1708 ng/mL’’
PostbaricitinibY therapy
Prednisolone / 30 mg OD 15 mg OD
Methotrexate / 20 mg 1 weekly /
Other DMARD / / /
x At time of baricitinib implementation. YAt first follow-up (8±2weeks) after implementation of a stable dose of baricitinib. ‘’The elevation of ferritin
does not correspond to disease flares but likely reflects increased transfusion dependence.
BD, two times per day; CRP, C reactive protein; DMARD, disease modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; NA, not
available; OD, one time per day.
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on two-weekly intravenous tocilizumab monotherapy,
successfully resulting in complete symptomatic control
for 4 years. Subsequently, the patient developed chilblain
vasculitis, deemed to have been caused by IL-6 blockade
itself (and replicated after receiving subcutaneous sarilu-
mab). The vasculitis, although seronegative, responded
to rituximab, but AOSD symptoms remained proble-
matic. A trial of anakinra failed due to intolerance; there-
fore, baricitinib was gradually introduced with careful
monitoring. The patient has remained in biochemical
and clinical remission for 9 months. At 7 months, she
developed Pneumocystis jirovecii pneumonia, which
responded to trimethoprim-sulfamethoxazole and she
remains on it prophylactically.
DISCUSSION
AOSD remains a diagnostic and therapeutic challenge
due to its myriad clinical manifestations and the con-
founding effects of comorbidities, partially effective
therapies and continually evolving phenotypes. Our
experience with baricitinib in biological-resistant AOSD
is highly variable, perhaps reflecting the varied clinical
presentation of this disease. One patient had pre-existing
MDS and subsequently developed a clinical syndrome,
which clinically resembled AOSD. Considering that
there was significant time interval (2 years) between diag-
nosis of MDS and eventual emergence of AOSD-like con-
dition, it could be argued that this was simply
coincidence, particularly since it is often considered that
AOSD tends to precede an eventual diagnosis of
malignancy.10 However, a number of studies have already
reported that autoimmune/autoinflammatory condi-
tions are more common in MDS than in the general
population, although with no clear classification of
these inflammatory disorders. The range of autoim-
mune/autoinflammatory disorders in patients with MDS
is highly variable with a prevalence rate ranging from 7%
to 30% according to the different studies.11 12 Therefore,
it is also reasonable to assume that AOSD-like condition
in P3 is possibly a complication of underlying MDS. Con-
sidering that a JAK1/2 inhibitor (ruxolitinib) is already
used in haematology to treat myelofibrosis, P3 response
to baricitinib might not be surprising. However, ruxoliti-
nib is typically approved for the treatment of intermedi-
ate-risk and high-risk myelofibrosis and associated
symptoms.13 Interestingly, P3 also developed an opportu-
nistic infection with pneumocystis while on baricitinib,
a complication previously described only once in the
context of myelofibrosis therapy with ruxolitinib.
The response to baricitinib in two other patients with
AOSD was mixed. Nonetheless, JAKi remains a promising
therapeutic option for patients otherwise dependent on
high-dose corticosteroids. A recent report from China
describes the successful use of tofacitinib in 14 patients
with AOSD; however, not all patients had a complete
response and some were still needing to take steroids on
a long-term basis.14 The success of JAKi in patients who
have failed IL-1-directed and IL-6-directed therapies
might be explained by the ability of these medications
to block other likely relevant cytokines such as IL-12/IL-
23 and interferon-γ. However, the optimal therapeutic
dose of JAKi used for AOSD might be different from
what is used for licenced indication. This point was illu-
strated by a recent report of baricitinb use in the treat-
ment of interferonopathies by Sanchez et al where larger,
treat-to-effect, dosages were used, raising the possibility of
underdosing in our cases.15
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